"The development of a new, cost-effective hardware platform has been in progress for some time now and we are proud to present the finished product," says Yvonne Mårtensson, CEO of CellaVision. "The product has been demonstrated to a number of potential customers and responses have been very positive. On this basis we are ready to launch the product in July. We will have a wider and stronger range of products, giving CellaVision a more competitive edge."
Using CellaVision's analyzers laboratories can achieve time reductions and more standardized analyses. The ratio between different types of white blood cells and their appearance are important criteria in diagnosis of a number of conditions such as infections and blood cancer. To count and classify them is therefore a very common routine analysis in hematology laboratories. Trends indicate that not only the larger, but also the medium-sized laboratories are keen on automating the analytical process. Increased automation gives lab personnel more time and increases objectivity, safety, and standardization in the analytical work.
CellaVision's current range of products consists of the analyzers CellaVision® DM96 and CellaVision® DM8 as well as software for remote access, and proficiency testing and education. Marketing of the CellaVision DM1200 will be aimed towards the same customer group as for the DM8 - the medium-sized laboratory. The new instrument is based on a new cost reduced hardware platform, is fully automated and has a wider range of uses.
The product was presented in mid-May in Istanbul at a scientific conference organized by the company's distributor Sysmex Europe, and received a very positive response by distributors and potential customers. The official product launch will take place at the international Annual Meeting & Clinical Lab Expo AACC in Chicago, USA, on July 20-24.
CellaVision DM1200 will be commercially available in Europe in July and will be sold by CellaVision and its network of distributors. The company will also apply for the various clearances necessary for selling the product in North America and Japan.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com
About CellaVision
CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.
CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.